



Lab resource: Stem cell line

Generation of KCL031 clinical grade human embryonic stem cell line



Laureen Jacquet^a, Victoria Wood^a, Neli Kadeva^a, Glenda Cornwell^a, Stefano Codognotto^a, Carl Hobbs^b, Emma Stephenson^a, Dusko Ilic^{a,*}

^a Stem Cell Laboratories, Division of Women's Health, Faculty of Life Sciences and Medicine, King's College London and Assisted Conception Unit, Guys' Hospital, London, United Kingdom

^b Histology Laboratory, Wolfson Centre for Age-Related Diseases, Faculty of Life Sciences and Medicine, King's College London, United Kingdom

ARTICLE INFO

Article history:

Received 26 December 2015

Accepted 29 December 2015

Available online 3 January 2016

ABSTRACT

The KCL031 human embryonic stem cell line was derived from a normal healthy blastocyst donated for research. The ICM was isolated using laser microsurgery and plated on γ -irradiated human foreskin fibroblasts. Both the derivation and cell line propagation were performed in an animal product-free environment and under current Good Manufacturing Practice (cGMP) standards. Pluripotent state and differentiation potential were confirmed by *in vitro* and *in vivo* assays.

© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

1. Resource table

Name of stem cell line	KCL031
Institution	King's College London, London UK
Derivation team	Neli Kadeva, Victoria Wood, Glenda Cornwell, Stefano Codognotto, Emma Stephenson
Contact person and email	Dusko Ilic, email: dusko.ilic@kcl.ac.uk
Date archived/stock date	Aug 02, 2011
Type of resource	Biological reagent: cell line
Sub-type	Human pluripotent stem cell line
Origin	Human embryo
Key marker expression	Pluripotent stem cell markers: NANOG, OCT4, TRA-1-60, TRA-1-81, alkaline phosphatase (AP) activity
Authentication	Identity and purity of line confirmed
Link to related literature (direct URL links and full references)	1) Jacquet, L., Stephenson, E., Collins, R., Patel, H., Trussler, J., Al-Bedaery, R., Renwick, P., Ogilvie, C., Vaughan, R., Ilic, D., 2013. Strategy for the creation of clinical grade hESC line banks that HLA-match a target population. <i>EMBO Mol. Med.</i> 5 (1), 10–17. doi: 10.1002/emmm.201201973 http://www.ncbi.nlm.nih.gov/pubmed/23161805
	2) Canham, A., Van Deusen, A., Brison, D.R., De Sousa, P., Downie, J., Devito, L., Hewitt, Z.A., Ilic, D., Kimber, S.J., Moore, H.D., Murray, H., Kunath, T., 2015. The molecular karyotype of 25 clinical-grade human embryonic stem cells

(continued)

Information in public databases	lines. <i>Sci. Rep.</i> 5, 17258. doi: 10.1038/srep17258 http://www.ncbi.nlm.nih.gov/pubmed/26607962
Ethics	3) Ilic, D., Stephenson, E., Wood, V., Jacquet, L., Stevenson, D., Petrova, A., Kadeva, N., Codognotto, S., Patel, H., Semple, M., Cornwell, G., Ogilvie, C., Braude, P., 2012. Derivation and feeder-free propagation of human embryonic stem cells under xeno-free conditions. <i>Cytotherapy.</i> 14 (1), 122–128. doi: 10.3109/14653249.2011.623692 http://www.ncbi.nlm.nih.gov/pubmed/22029654
	4) Stephenson, E., Jacquet, L., Miere, C., Wood, V., Kadeva, N., Cornwell, G., Codognotto, S., Dajani, Y., Braude, P., Ilic, D., 2012. Derivation and propagation of human embryonic stem cell lines from frozen embryos in an animal product-free environment. <i>Nat. Protoc.</i> 7 (7), 1366–1381. doi: 10.1038/nprot.2012.080 http://www.ncbi.nlm.nih.gov/pubmed/22722371
	KCL031 is a National Institutes of Health (NIH) registered hESC line NIH Registration Number: NIHhESC-14-0263 http://grants.nih.gov/stem_cells/registry/current.htm?id=672 The hESC line KCL031 is derived under license from the UK Human Fertilisation and Embryology Authority (research licence numbers: R0075 and R0133) and also has local ethical approval (UK National Health Service Research Ethics Committee Reference: 06/Q0702/90). Informed consent was obtained from all subjects and the experiments conformed to the principles set out in the WMA Declaration of Helsinki and the NIH Belmont Report. No financial inducements are offered for donation.

* Corresponding author.

E-mail address: dusko.ilic@kcl.ac.uk (D. Ilic).

2. Resource details

Consent signed	Nov 26, 2008
Embryo thawed	Jun 29, 2011
UK Stem Cell Bank Deposit Approval	Reference: SCSC12-37
Sex	Male 46, XY
Grade	Clinical
Disease status	Healthy/Unaffected
Karyotype (aCGH)	50 kb deletion at 7q22.3 (105,465,968–105,516,305).
SNP Array	Loss at 8q24.23 (136,718,037–136,837,768) (Canham et al., 2015)
DNA fingerprint	Allele sizes (in bp) of 16 microsatellite markers specific for chromosomes 13, 18 and 21 (Jacquet et al., 2013)
HLA typing	HLA-A 02, 24; B 51, 52; Bw 4; C 12, 14; DRB1 11, 15; DRB3 02; DRB5 01; DQB1 03, 06 (Jacquet et al., 2013; Canham et al., 2015)
Viability testing	Pass
Mycoplasma	Negative
Sterility	Pass
Pluripotent markers (immunostaining) (Fig. 1)	NANOG, OCT4, TRA-1-60, TRA-1-81, AP activity
Three germ layer differentiation in vitro (immunostaining) (Fig. 2)	Endoderm: AFP (α -fetoprotein) Ectoderm: TUBB3 (tubulin, beta 3 class III) Mesoderm: ACTA2 (actin, alpha 2, smooth muscle)
Three germ layer differentiation in vivo (teratomas) (Fig. 3)	Endoderm: AFP, GATA4 Ectoderm: TUBB3, GFAP (glial fibrillary acidic protein) Mesoderm: DES (desmin), Alcian Blue and periodic acid–Schiff (PAS)-stained cartilage
Targeted differentiation (Fig. 4)	Cardiomyocytes: TNNT2 (cardiac troponin T) immunostaining
Sibling lines available	No

We generated KCL031 clinical grade hESC line following protocols, established previously (Ilic et al., 2012; Stephenson et al., 2012), and now adapted to cGMP conditions. The expression of the pluripotency markers was tested after freeze/thaw cycle (Fig. 1). Differentiation potential into three germ layers was verified in vitro (Fig. 2) and in vivo (Fig. 3), as well as targeted differentiation into cardiac myocytes (Fig. 4).

Molecular karyotyping using array comparative genomic hybridization aCGH identified deletion at 7q22.3 (105,465,968–105,516,305). Whole-genome single nucleotide polymorphism (SNP) array analysis detected loss at 8q24.23 (136,718,037–136,837,768) (Canham et al., 2015). The gain contains no genes and it has been also reported previously to occur in healthy individuals from worldwide population (Macdonald et al., 2014). Estimated frequency in the human population is 3.85% (Canham et al., 2015).

Donors were tested negative for Human Immunodeficiency Virus 1 (HIV1), Hepatitis B (HepB, HCB) and C Virus (HepC, HCV). We did not retest the line.

We also generated research grade of KCL031 line that is adapted to feeder-free conditions.

3. Materials and methods

3.1. Consenting process

We distribute Patient Information Sheet (PIS) and consent form to the in vitro fertilization (IVF) patients if they opted to donate to research embryos that were stored for 5 or 10 years. They mail signed consent back to us and that might be months after the PIS and consent were mailed to them. If in meantime new versions of PIS/consent are implemented, we do not send these to the patients or ask them to re-sign; the whole process is done with the version that was given them initially. The PIS/consent documents (FRO-V.5) were created on Aug. 10, 2007. HFEA Code of Practice that was in effect at the time of document creation: Edition 7 – R.1 (<http://www.hfea.gov.uk/2999.html>). The donor




Fig. 1. Expression of pluripotency markers. Pluripotency is confirmed by immunostaining (Oct4, Nanog, TRA-1-60, TRA-1-81) and alkaline phosphatase (AP) activity assay. Actin stress fibers, visualized with rhodamine-phalloidin (red), are present in both feeders and hES cell colonies, whereas AP activity (green) is detected only in hES cells. Scale bar, 10 µm.

Download English Version:

<https://daneshyari.com/en/article/2094337>

Download Persian Version:

<https://daneshyari.com/article/2094337>

[Daneshyari.com](https://daneshyari.com)